Cancer · 2002 · 70 citations · 17 references
MedicineOncologyOtolaryngologyCancer ImmunologyImmunotherapyOncologic SurgeryCancer ImmunotherapyImmunotherapy For Oral CancerOral Cavity CancerOropharyngeal CancerDisease-free Survival AnalysisDisease-free Survival AssessmentRadiotherapy For Oral Cancer
BACKGROUND: The current randomized, multicenter, Phase III trial was conducted to determine whether the disease free interval and overall survival of patients with T2-T4,N0-N3,M0 squamous cell carcinoma (SCC) of the oral cavity or oropharynx could be extended through the combination of surgery (and radiotherapy, if required) with perilymphatic recombinant IL-2 (rIL-2). METHODS: Patients with a resectable T2-T4,N0-N3,M0 SCC of the oral cavity and oropharynx were assigned randomly to receive surgery and radiotherapy or to receive IL-2, surgery, and radiotherapy. Five thousand units of rIL-2 were injected around the ipsilateral cervical lymph node chain daily for 10 days before surgery. After surgery, contralateral 5-day rIL-2 courses were administered monthly for 1 year. The differences in disease free and overall survival between the two groups of patients were evaluated statistically. RESULTS: Two hundred two patients finished the study. No significant complications related to rIL-2 were encountered, and surgery and radiotherapy were not hampered by its prior administration. Multivariate analysis conducted to determine the extent to which survival was influenced by rIL-2 and the other variables showed that rIL-2 significantly lengthened disease free survival (P < 0.01) and that this resulted in longer overall survival (P < 0.03). CONCLUSIONS: The data emerging from this trial indicate that perilymphatic administration of low, nontoxic doses of rIL-2 is a simple and manageable way to delay recurrences of SCC.
17
C. C. Boring, T. S. Squires, T. Tong et al. · CA A Cancer Journal for Clinicians · 1994 · 1.3K citations · Full text
TNM classification of malignant tumours
A.M. Cassoni · Clinical Oncology · 1998 · 1.2K citations
Federica Cavallo, Mirella Giovarelli, G Forni et al. · JNCI Journal of the National Cancer Institute · 1997 · 172 citations · Full text
Life Sciences, Immunology, Oncology +17